Back to discover
Disease

Connective Tissue Diseases

Late-stage therapeutic developmentEmerging research
MeSHConnective Tissue Diseases
1
Publications
16
Clinical trials
12
Associated genes
1
Related proteins
2017
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Clinical Milestones7View
Results expected 2
Recently completed 4
Other updates 1
Activity timeline7

Clinical trials

11 sponsors · 0 new · 1 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
16
All trials
6
Active
5
Late-stage
6
Completed
Late-stage studies

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Phase 4 · Recruiting · Regionshospitalet Silkeborg

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

Phase 3 · Recruiting · GlaxoSmithKline

A Superiority Study Comparing Two Pharmaceutical Skin Care Creams Containing Different Humectants with a Non-humectant Containing Skin Care Cream for the Treatment of Xerotic Foot of Persons with Diabetes

Phase 4 · Recruiting · Malmö University

An Investigator-Initiated, Phase 4, Open-Label, Single-Arm, Single-Center Study Investigating the Residual Disease Memory in Psoriasis Skin During Enstilar® and Narrow-Band Ultraviolet B Therapy: The Mempsolar Study

Phase 4 · Active, not recruiting · Aarhus University Hospital

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH

Phase 3 · Completed · United Therapeutics
Recruiting

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Phase 4 · Recruiting · Regionshospitalet Silkeborg

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

Phase 3 · Recruiting · GlaxoSmithKline

A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Phase 2 · Recruiting · Beijing Hospital

Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I/IIa Clinical Trial

Phase 1/2 · Recruiting · China Medical University Hospital

A Superiority Study Comparing Two Pharmaceutical Skin Care Creams Containing Different Humectants with a Non-humectant Containing Skin Care Cream for the Treatment of Xerotic Foot of Persons with Diabetes

Phase 4 · Recruiting · Malmö University
Recently completed

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH

Phase 3 · Completed · United Therapeutics

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Early Phase 1 · Completed · Premier Specialists, Australia

A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LEO 90100 Aerosol Foam Compared to Betesil® Medicated Plaster in the Treatment of Psoriasis Vulgaris

Phase 2 · Completed · LEO Pharma

A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis Vulgaris

Phase 2 · Completed · LEO Pharma

A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin

Phase 1 · Completed · LEO Pharma

Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Phase 1 · Completed · LEO Pharma

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites
Recent publications

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites
Leading journals1
  • American journal of medical genetics. Part C, Seminars in medical genetics1
Leading researchers7
  • Berglund B1
  • Castori M1
  • Cohen H1
  • Grahame R1
  • Kazkaz H1
  • Levy H1
  • Tinkle B1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SOX90.47TRIP110.46WDR190.45COL9A10.44NEK10.41CBS0.41PEX70.39ANKRD550.38STAMBPL10.36PCDH170.33MYO100.33CDCA7L0.32

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Cystathionine beta-synthasevia CBS0.41

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.

Identifiers
MeSHConnective Tissue Diseases
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.